Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle

May 22 2012

• By Sue Sutter

Related Content

<em>Brilinta</em> Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

Jan 01 2012

FDA Advice On Missing Data May Be To Avoid Missing It In The First Place

Mar 01 2012

Xarelto Approval For DVT Bodes Well For Coming Indications

Jul 05 2011

Low-Dose Xarelto Effective In ACS Patients

Nov 14 2011

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Nov 04 2011

Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data

Aug 16 2010

Related Companies

Johnson & Johnson

Bayer AG

Johnson & Johnson

AstraZeneca PLC

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window